The role of pre-operative axillary ultrasound in assessment of axillary tumor burden in breast cancer patients: a systematic review and meta-analysis Vivian ManWing-Pan LukAva Kwong Review 22 September 2022 Pages: 245 - 254
TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer Hideki WatanabeHiroshi NakagomiMasao Omata Preclinical study 10 September 2022 Pages: 255 - 266
Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy Minyan ChenShengmei LiFangmeng Fu Preclinical study 13 September 2022 Pages: 267 - 277
Molecular characterization of ESR1 variants in breast cancer Arielle L. HeekeAndrew ElliottAntoinette R. Tan Preclinical study 20 September 2022 Pages: 279 - 289
Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer Hikari JimboYoshiya HorimotoJunichiro Watanabe Preclinical study 26 September 2022 Pages: 291 - 298
A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast Aparna GundaMallikarjuna S. EshwaraiahManjiri M. Bakre Clinical trial Open access 10 September 2022 Pages: 299 - 310
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958) Marc ThillPauline WimbergerAndreas Schneeweiss Clinical trial Open access 12 September 2022 Pages: 311 - 321
Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer Gabriel Francisco Pereira AleixoStephanie A. ValenteHalle C. F. Moore Clinical trial 17 September 2022 Pages: 323 - 328
Impact of body mass index on survival in women receiving chemotherapy for early breast cancer Rossanna C. PezoKelvin K. W. ChanMaureen Trudeau Clinical trial 17 September 2022 Pages: 329 - 339
Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer Yuka InoueMakoto FujishimaShinji Ohno Clinical trial Open access 24 September 2022 Pages: 341 - 348
Positive association between body height and breast cancer prevalence: a retrospective study with 135,741 women in Germany Niklas GremkeSebastian GriewingKarel Kostev Epidemiology Open access 10 September 2022 Pages: 349 - 354
Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis Yael LaitmanSarah M. NielsenEitan Friedman Epidemiology 12 September 2022 Pages: 355 - 361
Early postoperative psychological distress as a mediator of subsequent persistent postsurgical pain outcomes among younger breast cancer patients Jenna M. WilsonCarin A. ColebaughKristin L. Schreiber Epidemiology 14 September 2022 Pages: 363 - 370
Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center Luca NicosiaGermana LissidiniPaolo Veronesi Epidemiology Open access 17 September 2022 Pages: 371 - 377
Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009–2016: a cross-sectional study Anushri ChitkaraInes Mesa-EguiagarayJonine D. Figueroa Epidemiology Open access 18 September 2022 Pages: 379 - 387
Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer Anne Marie McCarthyAlisa K. ManningKatrina Armstrong Epidemiology 22 September 2022 Pages: 389 - 398
Are there differences in outcomes by race among women with metastatic triple-negative breast cancer? Bridget A. OppongAngel A. RolleElectra D. Paskett Epidemiology 24 September 2022 Pages: 399 - 408
Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017) Bo PanYing XuQiang Sun Epidemiology Open access 27 September 2022 Pages: 409 - 422
Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment Folnetti A. AlvarezHussein KaddourChioma M. Okeoma Brief Communication 17 September 2022 Pages: 423 - 437
Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients Kadri Altundag Letter to the Editor 10 September 2022 Pages: 439 - 439
